At a glance
ClinicalIndex Comparison RecordN/ACompleted· 228 enrolled
Drug / intervention
histamine-2 receptor antagonist +1 moredrug
Likely dose
histamine-2 receptor antagonist 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer
In Brief
A clinical study evaluating histamine-2 receptor antagonist and Placebo for Peptic Ulcer. Completed, enrolled 228 participants across 1 site.
Detailed Summary
Whether H2 receptor antagonist can prevent thienopyridine-related peptic ulcer remains unclear.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeptic Ulcer
CountriesTaiwan
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2012
First PostedApr 2015
Primary CompletionOct 2017
TodayJul 2026
First PostedApr 16, 2015
Enrollment StartJan 1, 2012
Primary CompletionOct 1, 2017
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 11.2 years ago
Interventions
histamine-2 receptor antagonistdrug
famotidine 40 mg qd plus thienopyridine
Placebodrug
placebo plus thienopyridine